Which spine, orthopedic device company lost the most last quarter? 18 points of comparison

Laura Dyrda -   Print  | Email

Many medical device companies reported steep declines in their orthopedics and spine businesses in the last quarter due to the postponement and cancellation of elective procedures during the pandemic.

Here are 18 points of comparison from Medtronic, Johnson & Johnson, Stryker, Zimmer Biomet, Smith+Nephew and NuVasive.

Medtronic (fourth quarter of the FY)
1. Revenue: $6 billion (26 percent decline)
2. Restorative therapy group, including spine, revenue: $7.725 billion (5.6 percent decline)
3. Spine revenue: $480 million (31 percent decline)

Full report

Johnson & Johnson Orthopedics
1. Sales: $2 billion (7.5 percent decline)
2. Trauma sales: $654 million (4.5 percent decline)
3. Spine, sports and other: $703 million (10 percent decline)

Full story

Stryker
1. Net sales: $3.6 billion (2 percent increase)
2. Orthopedic sales: $1.2 billion (2.1 percent decline)
3. Spine and nanotechnology sales: $700 million (0.7 percent increase)

Full report

Zimmer Biomet
1. Net sales: $1.78 billion (9.7 percent decline)
2. Net loss: $509 million
3. Spine, Dental, craniomaxillofacial revenue: $252 million (12.4 percent decline)

Full report

Smith+Nephew
1. Revenue: $1.1 billion (7.6 percent decline)
2. Orthopedic revenue: $497 million (9 percent decline)
3. Sports medicine and ENT revenue: $328 million (11 percent decline)

Full report

NuVasive
1. Revenue: $259.9 million (5.4 percent decline)
2. Net income: $5.3 million (43.6 percent decline)
3. The company made executive compensation cuts and pulled back on discretionary spending due to the pandemic.

Full report

More articles on devices:
Medtronic's pipeline includes spine, robotics innovations despite pandemic setbacks
3 spine, neurosurgery device recalls in the past year
Aetna to cover sacroiliac joint fusion under new policy

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.